Real-World Data for Ibrutinib in Relapsed/Refractory MCL

January 15, 2019

Kris Patel, MD, discusses the real-world data for treatment with ibrutinib in patients with relapsed/refractory mantle cell lymphoma as compared to clinical trials.

Kris Patel, MD, an oncologist at the Swedish Cancer Institute, discusses the real-world data for ibrutinib (Imbruvica) in patients with relapsed/refractory mantle cell lymphoma (MCL) as compared to clinical trials.

Patel says there were 2 major takeaways from these data. First, the overall response and clinical benefit was about the same between the real-world population and the clinical trial results. This shows that the response in the real-world can mirror those in a clinical trial.